...
机译:靶向CAR T细胞靶向BCMA治疗多发性骨髓瘤的临床前评价
Allogene Therapeut Inc 210 E Grand Ave San Francisco CA 94080 USA;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Allogene Therapeut Inc 210 E Grand Ave San Francisco CA 94080 USA;
Allogene Therapeut Inc 210 E Grand Ave San Francisco CA 94080 USA;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Cellectis SA 8 Rue Croix Jarry F-75013 Paris France;
Cellectis Inc 430 East 29th St New York NY 10016 USA;
Allogene Therapeut Inc 210 E Grand Ave San Francisco CA 94080 USA;
Cellectis Inc 430 East 29th St New York NY 10016 USA;
Cellectis SA 8 Rue Croix Jarry F-75013 Paris France;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Allogene Therapeut Inc 210 E Grand Ave San Francisco CA 94080 USA;
Cellectis SA 8 Rue Croix Jarry F-75013 Paris France;
Cellectis Inc 430 East 29th St New York NY 10016 USA;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Allogene Therapeut Inc 210 E Grand Ave San Francisco CA 94080 USA;
Pfizer Worldwide Res &
Dev Pfizer Canc Immunol Discovery 230 E Grand Ave San Francisco CA 94080;
Allogene Therapeut Inc 210 E Grand Ave San Francisco CA 94080 USA;
机译:靶向CAR T细胞靶向BCMA治疗多发性骨髓瘤的临床前评价
机译:CD3双特异性和ADC算法靶向BCMA治疗多发性骨髓瘤的临床前疗效与安全比较
机译:Allo-715,异构BCMA汽车T治疗,用于治疗多发性骨髓瘤的开关
机译:硫化砷纳米粒子在体外治疗多发性骨髓瘤细胞治疗的体外测试
机译:改善多发性骨髓瘤结果的策略:靶向MEK,HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植
机译:靶向BCMA的同种异体CAR T细胞治疗多发性骨髓瘤的临床前评价
机译:对靶向BCMA治疗多发性骨髓瘤的同种异体型汽车T细胞的临床前评价